"The U.S. Food and Drug Administration approved Xiidra (lifitegrast ophthalmic solution) for the treatment of signs and symptoms of dry eye disease, on Monday, July 11, 2016. Xiidra is the first medication in a new class of drugs, called lymphocyt"...
Intravenous infusion of up to 3 mcg/kg in healthy volunteers produced mean plasma concentrations 200 times higher than during clinical treatment and no adverse reactions were observed. Intravenous dosages of 5.5 to 10 mcg/kg caused abdominal pain, dizziness, fatigue, hot flushes, nausea, and sweating.
If overdosage with XALATAN occurs, treatment should be symptomatic.
Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/16/2014
Additional Xalatan Information
Xalatan - User Reviews
Xalatan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get breaking medical news.